This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, C. I. Articles by Daling, J. R. Search for Related Content PubMed PubMed Citation Articles by Li, C. I. Articles by Daling, J. R.

Changes in Breast Cancer Incidence Rates in the United States by Histologic Subtype and Race/Ethnicity, 1995 to 2004

Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

Requests for reprints: Christopher I. Li, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M4-C308, P. O. Box 19024, Seattle, WA 98109-1024. Phone: 206-667-7444. E-mail: cili{at}fhcrc.org

Breast cancer incidence rates rose throughout the 1980s and 1990s in the United States but have recently declined through 2004. Studies reporting this decline primarily attribute it to the sharp decline in menopausal hormone use following publication of the Women's Health Initiative trial results. However, they have not stratified rates by either histologic type or race/ethnicity, which could further inform contributors to these trends. Using data from 13 cancer registries that participate in the Surveillance, Epidemiology, and End Results program, we evaluated annual percent changes (APC) in breast cancer incidence rates from 1995 to 2004 by histologic type and race/ethnicity for intervals identified using joinpoint regression. Invasive ductal carcinoma and invasive lobular carcinoma incidence rates fell steadily from 1998 to 2004 [APC, –3.07% (95% confidence interval, –4.10 to –2.02) and APC, –3.18% (95% confidence interval, –5.18 to –1.03), respectively]. Declines in rates of breast cancer overall and invasive ductal carcinoma were primarily limited to women 50 years of age and to non-Hispanic whites and Asian/Pacific Islanders, and declines in rates of invasive lobular carcinoma were primarily limited to non-Hispanic whites. The majority of these declines began around 1998 and all began before 2002 when the Women's Health Initiative trial results were published; thus, the abrupt decline in hormone therapy use starting in 2002 is unlikely to be primarily responsible for the recent decline in breast cancer rates. The declines observed thus far are likely attributable to saturation of screening, although further declines related to the widespread cessation of hormone use may follow. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2773–80)

This article has been cited by other articles:

				R. M. Pfeiffer, A. Mitani, R. K. Matsuno, and W. F. Anderson Racial Differences in Breast Cancer Trends in the United States (2000-2004) J Natl Cancer Inst, May 21, 2008; 100(10): 751 - 752. [Full Text] [PDF]

				S. Brown Combined hormone therapy 'increases risk of lobular breast cancer after just three years of use' Menopause Int, March 1, 2008; 14(1): 2 - 4. [Full Text] [PDF]

				N. Patani, F. Jouhra, K. Mokbel, and K. Mokbel Changes in Breast Cancer Incidence Rates Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 742 - 742. [Full Text] [PDF]